---

Neuroplasticity

Definition

---

Types of Neuroplasticity

1. Synaptic Plasticity

2. Structural Plasticity

• Dendritic remodeling — growth, retraction, or reshaping of dendritic spines and branches
• Axonal sprouting — formation of new axonal branches and connections
• Synaptogenesis — formation of entirely new synapses
• Synaptic pruning — elimination of weak or unused synapses (critical during development and adolescence)
• Changes in myelination — experience can alter the thickness and extent of myelin sheaths, affecting conduction velocity

3. Neurogenesis

• Hippocampal dentate gyrus (important for memory and mood regulation)
• Olfactory bulb (via the subventricular zone)

4. Cortical Remapping

• Use-dependent expansion: Regions controlling heavily-used body parts or skills physically expand (e.g., larger somatosensory representation of the fingers in musicians).
• Cross-modal plasticity: Sensory-deprived cortex is recruited by other modalities (e.g., the visual cortex processes touch and sound in the blind).
• Injury-induced remapping: After focal brain damage, adjacent or homologous areas in the opposite hemisphere can take over lost functions.

---

Cellular and Molecular Mechanisms

Hebbian Plasticity — "Cells that fire together, wire together"

Molecular Cascade of LTP (NMDA-dependent)

1. Glutamate binds AMPA receptors → depolarization of postsynaptic membrane
2. Depolarization relieves Mg²⁺ block of NMDA receptors
3. Ca²⁺ influx through NMDA receptors activates CaMKII (Ca²⁺/calmodulin-dependent protein kinase II)
4. CaMKII phosphorylates existing AMPA receptors (increasing conductance) and triggers insertion of more AMPA receptors into the synapse
5. For long-lasting LTP: activation of CREB (cAMP response element-binding protein) → transcription of plasticity genes → new protein synthesis → structural synaptic changes

Key Molecular Players

---

Developmental vs. Adult Plasticity

Critical Periods

• Example: Binocular vision — if one eye is occluded in early childhood (amblyopia), the deprived eye's cortical representation is permanently diminished. This same occlusion in adulthood causes no lasting change.
• Critical periods are governed by the balance of excitatory/inhibitory (E/I) inputs and the maturation of parvalbumin-positive interneurons and perineuronal nets (extracellular matrix structures that stabilize circuits).

Adult Plasticity

• Skill learning (motor, cognitive)
• Memory formation and consolidation
• Recovery from injury
• Adaptation to sensory loss

---

Plasticity in Learning and Memory

1. Synaptic consolidation — occurs within hours; depends on NMDA receptor activation, protein synthesis, and AMPA receptor insertion at synapses
2. Systems consolidation — occurs over weeks to years; memories initially dependent on the hippocampus gradually become stored in neocortical networks

---

Plasticity After Brain Injury

---

Clinical and Therapeutic Applications

Rehabilitation Medicine

• Constraint-Induced Movement Therapy (CIMT): Restraining the unaffected limb forces use of the paretic limb, driving cortical remapping in stroke patients.
• Repetitive task practice and motor imagery both drive use-dependent plasticity.
• Robotic-assisted rehabilitation and virtual reality provide high-dose, repetitive training to engage plasticity mechanisms.

Neurostimulation

• Transcranial Magnetic Stimulation (TMS): Focal magnetic pulses can induce LTP- or LTD-like changes and modulate cortical excitability.
• Transcranial Direct Current Stimulation (tDCS): Weak electrical currents shift membrane potential, priming neurons for activity-dependent plasticity.
• Deep Brain Stimulation (DBS): Used in Parkinson's disease and depression; mechanisms may include plasticity-mediated circuit normalization.

Pharmacology

• SSRIs/SNRIs: Increase BDNF expression and promote neurogenesis in the hippocampus (contributing to antidepressant effects)
• Ketamine (NMDA antagonist): Paradoxically produces rapid synaptic potentiation via AMPA receptor upregulation — the basis for its rapid antidepressant action
• D-cycloserine: NMDA partial agonist used to enhance fear extinction in PTSD treatment
• Ampakines: Positive modulators of AMPA receptors under investigation for cognitive enhancement

Sensory Substitution and Prosthetics

• Brain-computer interfaces (BCIs) leverage plasticity to allow the brain to learn to control external devices or interpret novel sensory streams.
• Cochlear implants and retinal prostheses work because the auditory/visual cortex remains plastic enough to decode artificial electrical signals.

---

Factors That Promote or Impair Neuroplasticity

Promoting Factors

Impairing Factors

---

Maladaptive Neuroplasticity

• Chronic pain: Central sensitization in the dorsal horn and somatosensory cortex — LTP-like changes amplify pain signals (wind-up phenomenon)
• Addiction: Drug-induced dopamine surges drive pathologically strong LTP in the nucleus accumbens and prefrontal-limbic circuits, encoding compulsive drug-seeking
• PTSD: Hyperconsolidation of fear memories via amygdala LTP; impaired hippocampal contextual encoding
• Phantom limb pain: Remapping of the somatosensory cortex after amputation — adjacent body part representations invade the deafferented zone
• Tinnitus: Maladaptive reorganization of auditory cortex after cochlear damage
• Dystonia: Abnormal motor learning in the basal ganglia–cortical circuits (e.g., musician's dystonia)

---

Summary

---

Diabetic Neuropathy: Detailed Patient Assessment & Management

---

1. Overview & Epidemiology

---

2. Classification of Diabetic Neuropathy

---

3. Pathophysiology

Metabolic Pathways

• Polyol pathway: Excess glucose → sorbitol (via aldose reductase) → fructose; depletes NADPH and reduces glutathione → oxidative stress
• Advanced Glycation End-products (AGEs): Cross-link proteins, activate RAGE receptors → inflammation and endothelial dysfunction
• Protein kinase C (PKC) activation: Triggered by diacylglycerol accumulation → vascular dysfunction and decreased NO production
• Hexosamine pathway: Excess flux → impaired insulin signaling, inflammation

Vascular Mechanisms

• Endoneurial microangiopathy (thickening of basement membrane, reduced blood flow)
• Hypoxia-driven nerve ischemia
• Loss of vasa nervorum

Neurotrophin Deficiency

• Reduced nerve growth factor (NGF) and BDNF → impaired axon maintenance and regeneration

Neuroinflammation

• Activated macrophages, Schwann cell dysfunction, cytokine-mediated axonal injury

Net Effect

• Axonal degeneration (dying-back pattern, longest fibers first) → small fiber loss (pain/temperature) before large fiber loss (vibration/proprioception)
• Segmental demyelination in severe cases

---

4. Clinical Presentation

Distal Symmetric Polyneuropathy (DPN)

Autonomic Neuropathy

---

5. Patient Assessment

5.1 History

• Symptom characterization: burning, tingling, numbness, pain, allodynia, weakness
• Distribution and onset: feet/hands, insidious vs. acute
• Temporal pattern: nocturnal worsening, relationship to activity
• Autonomic symptoms: dizziness on standing, erectile dysfunction, bloating, incontinence
• Functional impact: falls, difficulty walking, sleep disturbance
• Diabetes duration and glycemic control: HbA1c history
• Risk factors: hypertension, dyslipidemia, smoking, alcohol, hypothyroidism, B12 deficiency (especially if on metformin)
• Medications: neurotoxic drugs (chemotherapy, isoniazid, metronidazole)

5.2 Validated Screening Instruments

5.3 Physical Examination

Foot Inspection

• Skin: calluses, ulcers, fissures, dryness, color, temperature asymmetry
• Nails: onychomycosis, ingrown nails
• Deformities: hammer toes, claw toes, hallux valgus, Charcot arthropathy
• Pulses: dorsalis pedis, posterior tibial (screen for PAD)

Sensory Testing

Reflex Testing

• Ankle (Achilles) reflex: reduced or absent early in DPN
• Knee reflex: later involvement

Motor Examination

• Intrinsic foot muscle wasting
• Dorsiflexion/plantarflexion strength
• Gait analysis for ataxia or foot drop

5.4 Cardiovascular Autonomic Testing

• Heart rate variability (HRV): during deep breathing (E:I ratio) — most sensitive early test
• Valsalva ratio: sustained expiration at 40 mmHg — tests parasympathetic and sympathetic function
• Orthostatic blood pressure: measure supine then after 1 and 3 minutes standing; ≥20 mmHg systolic or ≥10 mmHg diastolic drop = orthostatic hypotension
• 30:15 ratio (ratio of longest R-R at beat 30 to shortest at beat 15 after standing)

5.5 Electrodiagnostic Studies (EDX)

5.6 Laboratory Workup

• HbA1c — glycemic control
• Fasting glucose / OGTT — if diabetes not yet confirmed
• Vitamin B12 (especially if on metformin)
• TSH — hypothyroidism
• Serum protein electrophoresis (SPEP) — paraproteinemia
• Renal function (eGFR, urinalysis) — uremic neuropathy
• Lipid panel
• Folate, B1 (thiamine)
• CBC — anemia
• ANA, ANCA, anti-Ro/La — if vasculitic cause suspected

---

6. Management

6.1 Glycemic Control — Foundation of Treatment

• Intensive glycemic control reduces the incidence and progression of DPN, particularly in T1DM (DCCT trial: 60% reduction in neuropathy risk with tight control)
• In T2DM, benefit is modest but real (UKPDS, ACCORD)
• Target HbA1c ≤7% (individualized; avoid hypoglycemia in autonomic neuropathy with unawareness)
• Avoid glycemic variability — large fluctuations may worsen nerve damage independently of mean glucose

6.2 Cardiovascular Risk Factor Management

• Blood pressure control: Target <130/80 mmHg (ADA); ACE inhibitors/ARBs preferred in DM
• Lipid management: Statins; LDL target <70 mg/dL in high-risk patients
• Smoking cessation: Tobacco is an independent risk factor for DPN progression
• Weight management: Obesity worsens neuropathy; bariatric surgery has shown neuropathy improvement

6.3 Pharmacological Treatment of Painful DPN

First-Line Agents

Second-Line Agents

Topical/Adjunctive

Opioids

• Generally avoided as first- or second-line due to addiction risk, tolerance, and poor long-term outcomes
• Considered only after failure of multiple first/second-line agents
• If used: prefer extended-release, lowest effective dose, with regular reassessment

Combination Therapy

• Combining agents from different classes (e.g., duloxetine + pregabalin) can provide additive benefit with potentially lower doses of each — supported by the COMBO-DN trial

6.4 Autonomic Neuropathy Management

Cardiovascular Autonomic Neuropathy (CAN)

• Orthostatic hypotension: volume expansion (adequate salt/fluid intake), compression stockings, elevate head of bed, fludrocortisone, midodrine, droxidopa
• Resting tachycardia: beta-blockers (with caution in hypoglycemia unawareness)
• Exercise: gradual, supervised; avoid rapid postural changes

Gastroparesis

• Small, frequent low-fat/low-fiber meals
• Metoclopramide (1st-line prokinetic; limit use to <12 weeks due to tardive dyskinesia risk)
• Domperidone (less CNS penetration; preferred in many countries)
• Erythromycin (motilin agonist; short-term use)
• Pyloric botulinum toxin injection in refractory cases
• Gastric electrical stimulation (GES) for severe, refractory gastroparesis

Diabetic Diarrhea

• Loperamide; cholestyramine; clonidine in refractory cases
• Antibiotics for bacterial overgrowth (tetracycline, metronidazole)

Neurogenic Bladder

• Scheduled voiding (q3-4h)
• Alpha-blockers (tamsulosin) for outlet obstruction
• Bethanechol (parasympathomimetic) for detrusor underactivity
• Intermittent catheterization for significant retention

Erectile Dysfunction

• PDE5 inhibitors (sildenafil, tadalafil, vardenafil) — first-line
• Vacuum erection devices, intracavernosal injections in non-responders

Hypoglycemia Unawareness

• Strict avoidance of hypoglycemia for several weeks can partially restore awareness
• Continuous glucose monitoring (CGM) is strongly recommended
• Relaxing HbA1c targets may be necessary

6.5 Non-Pharmacological Management

Foot Care (Critical for LOPS patients)

• Daily foot inspection by patient (mirror for soles)
• Podiatry referral — nail trimming, callus debridement, ulcer management
• Therapeutic footwear: extra-depth shoes, custom orthotics, offloading devices (total contact cast for Charcot/ulcers)
• Patient education: never walk barefoot; proper nail care; avoid heating pads
• Wound care teams for active ulcers

Physical Activity & Exercise

• Aerobic exercise improves glycemic control and has direct neuroregenerative effects (increases BDNF, promotes nerve fiber regeneration)
• Balance training reduces fall risk significantly
• Aquatic therapy for patients with painful allodynia (reduces weight-bearing pain)

Neuromodulation

• Spinal cord stimulation (SCS): for refractory painful DPN not responding to pharmacotherapy; significant evidence base for pain reduction and improved QoL
• Transcutaneous electrical nerve stimulation (TENS): modest evidence; useful as adjunct
• Frequency-specific microcurrent: emerging evidence

Psychological Support

• Cognitive-behavioral therapy (CBT) for chronic pain management
• Mindfulness-based stress reduction (MBSR)
• Screening and treatment for depression and anxiety (highly comorbid with painful DPN)

---

7. Monitoring and Follow-Up

---

8. Prognosis

• DPN is slowly progressive but partially reversible with excellent glycemic control, particularly early in the course
• Small fiber neuropathy may show regeneration on serial skin biopsy after metabolic optimization
• Autonomic neuropathy (especially CAN) is associated with a 3–5× increased mortality risk, primarily from silent myocardial ischemia and sudden cardiac death
• Foot complications remain a major source of morbidity — approximately 15–25% of diabetic patients will develop a foot ulcer; 80% of amputations are preceded by an ulcer
• Early identification and intensive management significantly improve outcomes

---

9. Summary Algorithm

All diabetic patients → Annual foot exam (monofilament, vibration, inspection)
         ↓
Symptoms present?
   Yes → Characterize (DPN vs. autonomic vs. focal)
   No  → Continue surveillance; optimize glycemic/CV risk factors
         ↓
Confirm diagnosis → MNSI / NCS / skin biopsy (small fiber) / autonomic testing
         ↓
Treat underlying diabetes: HbA1c target, CV risk factors, smoking cessation
         ↓
Painful DPN? → Step-up pharmacotherapy:
  1st line: Duloxetine or Pregabalin (or TCA if no cardiac contraindication)
  2nd line: Add second agent from different class (combination)
  3rd line: Tapentadol, tramadol, capsaicin 8% patch
  Refractory: Spinal cord stimulation
         ↓
Autonomic neuropathy? → System-specific management (orthostasis, gastroparesis, bladder, ED)
         ↓
Foot at risk (LOPS)? → Therapeutic footwear, podiatry, patient education, wound care

---